Most appendix cancer cases sit buried inside colorectal datasets or locked inside the single institution that treated them. That fragmentation is a main reason the science has moved slowly. A patient-led registry solves the supply problem at the source. It captures cases that registries miss, long-tail outcomes that never reach a chart note, and patient-reported detail that traditional records ignore. It augments hospital records rather than replacing them.

A rare cancer only becomes tractable when its cases are gathered in one place. By pooling molecular results, treatment histories, and long-term outcomes across borders, the registry lets investigators ask questions a single institution could never power, such as how specific mutations respond to specific therapies, or how outcomes differ by subtype and grade. It also shortens the path from question to cohort. Instead of spending years assembling enough patients, an investigator can start from a structured, consented population that already exists. For patients, that means research moves faster. For the field, it means evidence built on more than a handful of scattered charts.

If you treat appendiceal cancer, your patients can contribute to the appendix cancer registry in about fifteen minutes from anywhere in the world. Pointing a patient to the registry costs nothing and strengthens the evidence base that every specialist relies on.